ERBB2 and breast carcinoma: Specifically, the Guidelines for the Diagnosis and Treatment of Breast Cancer (2021) issued by the Chinese Anti-Cancer Association recommend pyrotinib in combination with capecitabine for HER2-positive advanced breast cancer.